Is FUL a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Margin expansion from pricing and Quantum Leap, with revenue (ttm) at ~$3.55B; Q3 FY2026 revenue ~$938M, up ~5.2% year over year. The bear case rests on leverage is the first constraint: total debt of ~$2.19 billion against ~$97 million of cash already sits near 3x trailing EBITDA of ~$610 million, and the new 7.625% notes carry a coupon well above the 4.000% notes they partly replace, so interest cost rises as the AMS deal closes. Analysts covering it are spread from $62.00 to $80.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Leverage is the first constraint: total debt of ~$2.19 billion against ~$97 million of cash already sits near 3x trailing EBITDA of ~$610 million, and the new 7.625% notes carry a coupon well above the 4.000% notes they partly replace, so interest cost rises as the AMS deal closes. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $62.00, +20.8% from the $51.32 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Margin expansion from pricing and Quantum Leap. Adjusted EBITDA margin reached 19.1% in the second quarter of fiscal 2026, up ~70 basis points year over year, while adjusted gross margin gained ~200 basis points to 34.2%. The most optimistic analyst target on FUL is $80.00, +55.9% from the $51.32 price. That figure is only reachable if this thesis works close to its best case.

Leverage is the first constraint: total debt of ~$2.19 billion against ~$97 million of cash already sits near 3x trailing EBITDA of ~$610 million, and the new 7.625% notes carry a coupon well above the 4.000% notes they partly replace, so interest cost rises as the AMS deal closes. Buying a medtech business is also a step outside the industrial adhesives core, so integration and synergy delivery carry real execution risk. The margin gains lean heavily on price, which historically gives back some ground when petrochemical-derived raw material costs fall, and first-quarter results already showed supply disruption and force majeure notices from suppliers. Construction end markets served by Building Adhesive Solutions are rate-sensitive and cyclical, roughly 40% of revenue sits outside the Americas and is exposed to currency swings, and tariffs remain an unpredictable input. Finally, the activist situation can resolve in more than one direction, and an unaccepted carve-out bid, even a raised one, is not a floor under the share price. The most pessimistic published target is $62.00, +20.8% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

H.B. Fuller is the largest pure-play adhesives and sealants maker in the world, founded in 1887, selling into packaging, hygiene, construction and electronics.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Margin expansion from pricing and Quantum Leap) stalling in the reported numbers rather than in the narrative, the risk above (leverage is the first constraint: total debt of ~$2.19 billion against ~$97 million of cash already sits near 3x trailing EBITDA of ~$610 million, and the new 7.625% notes carry a coupon well above the 4.000% notes they partly replace, so interest cost rises as the AMS deal closes) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

H.B. Fuller formulates industrial adhesives, sealants and coatings, and is the largest pure-play adhesives company in the world with ~$3.55 billion in trailing revenue and ~7,100 employees. Its products bond diapers, tissue, food packaging and e-commerce cartons, assemble cars, electronics and appliances, and seal commercial roofs and flooring. The company was founded in St. Paul, Minnesota in 1887.

FUL trades on the New York Stock Exchange and can be bought through any US brokerage account that offers listed equities, in whole or fractional shares. Some investors hold it as a single position, while others treat it as one name inside a broader industrials or specialty chemicals allocation alongside peers like Sika, RPM International or Avery Dennison.

H.B. Fuller runs a fiscal year ending in late November, so its quarters are offset from the calendar. Third-quarter fiscal 2026 results, covering the period ended August 29, 2026, were released after the close on September 23, 2026, with adjusted EPS of $1.52 against a ~$1.46 consensus. The fourth quarter ends November 28, 2026, and those results are typically reported in January.